Wegovy has been shown to help patients lose as much as 15% of their weight on average
Triple Agonist vs Dual Agonist Comparison Contents Key Takeaways Two Compounds, One Manufacturer, Different Receptor Counts Weight Loss: The Numbers Side by Side Mechanism Breakdown: What the Third Receptor Adds Safety: Where the Tradeoffs Appear Evidence Quality: Phase 2 vs Phase 3 Where Each Compound Might Win The Bottom Line Explore Research Peptides Retatrutide 12mg 24.2% body weight lost (Phase 2, 48 wk) vs Tirzepatide 15mg 22.5% body weight lost (Phase 3, 72 wk) 3 vs 2 receptor targets (retatrutide vs tirzepatide) 63% vs 57% reached 20%+ weight loss (highest dose arms) Eli Lilly same manufacturer for both compounds Sources: Retatrutide Phase 2 (NEJM, 2023), SURMOUNT-1 (NEJM, 2022)
Join now Activity 260 followers Judith Stern Judith Stern 1yJudith Stern posted thisSince my last post, Ive started a new position with Intra Cellular Therapies, ITCI Inc
"I was like 'I bet the second I go off I'm going to get starving again,' and I did," Bader said
Notably, Richard et al
What should I avoid while using Trulicity
